DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: SILENOR

Summary for Tradename: SILENOR

Patents:9
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 SILENOR

Pharmacology for Tradename: SILENOR

Clinical Trials for: SILENOR

Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia
Status: Completed Condition: Sleep Initiation and Maintenance Disorders

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Status: Recruiting Condition: Lymphoma; Malignant Mesothelioma; Malignant Pericardial Effusion; Malignant Pleural Effusion; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Soft Tissue Sarcoma; Thymoma and Thymic Carcinoma

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Status: Recruiting Condition: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain

Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome
Status: Completed Condition: Irritable Bowel Syndrome

The Treatment of Insomnia in Patients With HIV Disease
Status: Completed Condition: HIV Infections; Insomnia

Treatments for Insomnia in Patients With Parkinson's Disease
Status: Recruiting Condition: Parkinson's Disease; Insomnia

Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Status: Completed Condition: Major Depression

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036Mar 17, 2010RXNo5,585,115<disabled>Y<disabled>
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036Mar 17, 2010RXNo5,725,884<disabled>Y<disabled>
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036Mar 17, 2010RXNo5,866,166<disabled>Y<disabled>
Pernix Theraps Llc
SILENOR
doxepin hydrochloride
TABLET;ORAL022036Mar 17, 2010RXNo5,948,438<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SILENOR

Drugname Dosage Strength RLD Submissiondate
doxepin hydrochlorideTablets3 mg and 6 mgSilenor9/16/2010

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc